Nordic Nanovector stock has been consolidating upon positive news about FDA Fast Track Status for Betalutin and amended patient eligibility criteria in the PARADIGME clinical trial, and looks set to draw a golden cross for the first time since the pre ASH rally of 2018.
Entrys should be made with keen eyes on risk management, but it is nice to see some good...
After a stellar 2016 (nanoinvestors.wordpress.com), things have been going downhill for the Nordic Nanovector stock.
After recently giving a sell signal by crashing through a triple bottom at NOK 68, investors are now looking to the NOK 40 line to see if it can provide support for a bounce.
